News summary produced by Claude AI
Defense Secretary Pete Hegseth unveiled a policy requiring testosterone deficiency screenings for service members aged 30 and older as part of annual physical examinations, with younger personnel eligible for voluntary testing. The announcement represents the latest effort by the current administration to promote testosterone replacement therapy, following similar endorsements from Health Secretary Robert F. Kennedy Jr. and recent FDA actions revising product labeling on testosterone treatments.
Medical experts expressed sharply differing perspectives on the initiative. Abraham Morgentaler, a faculty fellow at Harvard Medical School, argued that routine testosterone screening could provide valuable health insights comparable to standard tests for thyroid function or organ health. He contended that low testosterone correlates with significant medical conditions that might otherwise go undetected without testing. Morgentaler suggested that testosterone levels represent an important health indicator for men over 30 and expressed hope the practice would become standard across all medical settings.
Other specialists raised substantial concerns about the proposal. Adrian Dobs, an endocrinologist at Johns Hopkins University, identified multiple problems including variability in testing methods, the broad range of normal testosterone levels, and difficulty determining who genuinely requires treatment. She noted that most men would fall within normal ranges and questioned whether slightly low levels warrant intervention absent specific symptoms. Dobs highlighted particular concerns about testosterone therapy suppressing the body’s natural hormone production, with implications for reproductive function.
Helen Bernie, director of men’s sexual and reproductive health at Indiana University, acknowledged that military personnel face unique occupational stressors including intense physical training and chronic sleep deprivation that could affect testosterone levels. She suggested screening might have merit given these circumstances but cautioned that testing alone should not trigger automatic treatment. Current guidelines from major American medical organizations recommend against routine testosterone screening and advise that diagnosis requires both documented symptoms and repeated low morning test results alongside evaluation for reversible causes.
The Defense Department declined to provide additional details about implementation. Medical experts emphasized that any treatment should include thorough patient discussions about risks and continued monitoring, with approaches tailored to individual circumstances.